The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Genomic factors impacting survival in patients with myeloma without known cytogenetic risk features
Mehmet Samur, PhD, Dana-Farber Cancer Institute, Boston, MA, shares the results of a study that used whole-genomic sequencing (WGS) to identify factors that contribute to shorter survival in patients with multiple myeloma without known high-risk cytogenetic features. The study identified several genomic risk factors that are not traditionally considered as high-risk features, including increased genomic instability, increased mutational load, and alterations in chromosomes 8 and 16. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
